Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial management with controlled expenses and a positive cash position, despite a recent public offering. The strategic focus on Medicare coverage and commercialization of EsoGuard, paired with promising partnerships and expansion plans, is positive. However, uncertainties in the timeline for Medicare coverage and the need for more commercial payer support slightly temper the outlook. Overall, the sentiment leans positive due to the potential revenue growth and strategic partnerships, but the absence of a clear timeline for Medicare approval keeps it from being strongly positive.
Key Financial Performance
EsoGuard test volume 2,841 tests in Q3 2025, consistent with the previous quarter. This volume is within the target range of 2,500 to 3,000 tests per quarter, which is necessary to maintain engagements with commercial payers.
Revenue Approximately $1.2 million in Q3 2025, a 3% year-over-year increase. Revenue recognition is impacted by the transitional stage of reimbursement processes, with a significant portion of claims recognized upon collection rather than delivery.
Cash at quarter end $47.3 million as of September 30, 2025. This includes proceeds from a $27 million public offering completed during the quarter.
Quarterly burn rate $10.3 million in Q3 2025, consistent with the prior quarter and slightly better than the average burn rate of $10.5 million over the preceding four quarters.
Convertible debt $22 million 5-year note with a 12% interest rate and a $1 conversion price. The fair value decreased by $3 million in Q3 2025, reflecting stock price changes.
Shares outstanding Approximately 138 million shares as of the report date, including unvested restricted stock awards.
Non-GAAP operating expenses $11.5 million in Q3 2025, slightly lower than the trailing four-quarter average of $11.6 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EsoGuard test volume: 2,841 tests conducted in Q3 2025, generating approximately $1.2 million in revenue. This aligns with the target range of 2,500-3,000 tests per quarter.
Medicare coverage progress: Positive outcomes from the Medicare Contract Advisory Committee (CAC) meeting in September 2025. Clinical experts unanimously endorsed EsoGuard Medicare coverage, citing strong clinical evidence and guideline support. Anticipation of a draft Local Coverage Determination (LCD) soon.
Commercial payer engagement: Strengthened market access team to drive broader insurance coverage. UnitedHealthcare guidelines now mention EsoGuard, linking it to endoscopy guidelines, facilitating contracting discussions.
Firefighter Esophageal Cancer Prevention Summit: First summit to strengthen relationships with fire departments and promote EsoGuard testing for firefighters, a high-risk group for esophageal cancer.
Financial position: Completed a public offering, netting $27 million, ending Q3 with $47 million in cash. Quarterly burn rate of $10.3 million remains stable.
Revenue recognition: Revenue recognition remains transitional, with $1.2 million recognized in Q3, representing 17% of invoiced revenue. Medicare approval expected to significantly impact future revenue.
Market access team expansion: Recruited experienced professionals to lead payer engagement and national coverage strategy for EsoGuard.
Medicare reimbursement strategy: Implemented measures to target Medicare patients, aiming to maximize one-year look-back revenue upon Medicare coverage approval.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Coverage Uncertainty: The company is in the final stages of securing Medicare coverage for EsoGuard, but the process is not yet complete. Delays or unfavorable outcomes could impact revenue and strategic plans.
Revenue Recognition Challenges: Revenue is recognized only when claims are collected, not when tests are performed. This creates variability and uncertainty in financial reporting, especially as the company transitions its reimbursement process.
Dependence on Medicare Approval: Approximately 40-50% of the addressable patient population is Medicare-eligible. Delays in Medicare approval could significantly impact revenue and operational plans.
Commercial Payer Engagement: While progress is being made, the company is still in the process of securing broader commercial insurance coverage. Delays or challenges in these negotiations could hinder revenue growth.
Financial Sustainability: The company has a quarterly burn rate of $10.3 million and relies on external financing. While recent funding extends the runway through 2026, financial sustainability remains a concern if revenue growth does not materialize as expected.
Regulatory and Reimbursement Risks: The company faces risks related to regulatory approvals and reimbursement policies, which are critical for its business model and revenue generation.
Operational Execution: The company is scaling its market access team and infrastructure, but any missteps in execution could delay strategic milestones and impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Medicare Coverage: Lucid Diagnostics is in the final stages of securing positive Medicare coverage for EsoGuard. A draft Local Coverage Determination (LCD) is expected soon, followed by a 45-day public comment period and a final LCD publication. Once approved, the company can submit claims retroactively for up to one year.
Commercial Insurance Engagement: The company is actively engaging with commercial payers to secure broader insurance coverage for EsoGuard. Recent updates to UnitedHealthcare guidelines have strengthened the case for EsoGuard, linking it to existing endoscopy guidelines.
Market Access Team Expansion: Lucid has recruited a world-class market access team to drive payer engagement and secure reimbursement across major insurers. This team will also focus on government affairs and national coverage strategy for EsoGuard.
Revenue Projections: The company anticipates significant revenue growth upon securing Medicare coverage, as up to 50% of its target population is Medicare-eligible. Retroactive claims for Medicare patients could also contribute to revenue.
Firefighter Esophageal Cancer Prevention Summit: Lucid is hosting its first summit to strengthen relationships with fire departments and expand contracted event-based testing opportunities. This initiative is expected to bolster the pipeline of contracted testing events.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you share more about the dialogue at the recent CCLA meeting and the implications of a positive draft LCD?
A:The CCLA meeting was a regular meeting attended by Danielle, the new Head of Market Access. It provided an opportunity for open conversations with MolDX contractors. The meeting was positive, with 20-30 minutes dedicated to discussions about the company’s CAC meeting. The Head of MolDX reaffirmed the company’s perspective and stated that the necessary information to draft policy was obtained. A medical director from Noridian corroborated this sentiment. The draft LCD process is seen as a formality, as it involves flipping the policy from noncoverage to coverage without substantive changes.
Q:What is the expected timeline for the draft LCD issuance?
A:The company believes the timeline of year-end 2025 is reasonable. The process is seen as a workflow issue, and the shutdown did not significantly impact the issuance of LCDs. The data has been with MolDX for nearly a year, and the CAC meeting was positive, making the timeline feasible.
Q:Have there been any updates on dialogue with commercial payers?
A:Yes, there has been increased engagement with commercial payers, both large and small. The company has seen positive movement, with discussions strengthened by published guidelines and the inclusion of EsoGuard in updated guidelines by United. The company expects to see positive coverage policies from payers even before the Medicare process concludes.
Q:Could the end of the government shutdown accelerate the draft LCD process?
A:The shutdown did not slow down the LCD process significantly. The CAC group was out for a couple of weeks, but the administrative processes at CMS are expected to operate at full steam post-shutdown, potentially aiding the finalization of draft LCDs.
Q:What is the expected commercial channel mix by mid-2026?
A:The company is pushing to increase the portion of Medicare-eligible patients to at least 50%, aligning with the target population. Efforts are being made to engage health systems, which are motivated by the anticipation of Medicare coverage. Experienced director-level personnel have been brought in to focus on health systems.
Q:Why is the company focusing on Medicare patients now?
A:The company is confident about Medicare coverage being imminent and is intentionally pursuing Medicare-rich populations to maximize the 1-year lookback period for claims. This strategy aligns with the expectation of draft LCD issuance soon.
Q:What is the status of the NIH study on asymptomatic GERD patients?
A:The NIH study is enrolling well, with a target sample size of 600-900 patients. The VA is also conducting a parallel study with rapid enrollment. Results from these studies are expected to expand the target population from 30 million to 50 million, but they are not critical for the near-term commercial opportunity.
Q:What is the cost structure for EsoGuard tests, and has inflation impacted it?
A:The variable cost per test is approximately $200, with $50 for EsoCheck and $120-$125 for lab processing. Inflation has had negligible impact, and there is potential to reduce costs further through automation and AI.
Q:How many commercial payers currently cover EsoGuard?
A:One commercial payer, Highmark New York, has a positive policy for EsoGuard. The company is engaging with dozens of other payers to secure additional coverage.
Q:What is the conversion rate for EsoGuard referrals to completed tests?
A:The conversion rate for referred patients to completed tests is over 90%. For positive EsoGuard tests, 85% of patients comply with confirmatory endoscopy, which is double the compliance rate for patients referred without EsoGuard.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the exact timing of the draft LCD issuance, stating it as a workflow issue without committing to a specific date. Additionally, while they expressed confidence in Medicare coverage being imminent, they did not provide concrete evidence or a definitive timeline to support this claim.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CAC meeting
Cancer Prevention
Contract Advisory
Danielle
EGD
EsoGuard coverage
EsoGuard role
Esophageal Cancer
Firefighter Esophageal
GI guideline
Medicare patient
Prevention Summit
UnitedHealthcare
access payer
attendee
confidence meeting
conversation payer
course
coverage claim
department country
director
draft LCD
event testing
fire department
fire service
guideline endoscopy
language
leader
market access
momentum Medicare
offering
relationship
step
variety
LUCD Transcript
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Unknown5-14
Despite the 25% revenue growth and improved margins, the ongoing net loss and negative cash flow indicate financial challenges. The lack of discussion on strategic initiatives and operational updates limits visibility into future growth. However, the financial improvements and potential Medicare coverage provide some optimism, balancing the sentiment to neutral.
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call summary presents mixed signals. Basic financial performance shows growth in test volumes and revenue, but increased operating expenses and a significant net loss raise concerns. Positive developments include UnitedHealthcare coverage and increased Medicare mix, yet regulatory risks and unclear timelines for Medicare coverage finalization temper optimism. The Q&A session reveals cautious management and uncertainties, particularly regarding Medicare efforts and financial sustainability. Overall, the neutral sentiment reflects balanced positive and negative factors, suggesting limited short-term stock movement.
Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call highlights strong financial management with controlled expenses and a positive cash position, despite a recent public offering. The strategic focus on Medicare coverage and commercialization of EsoGuard, paired with promising partnerships and expansion plans, is positive. However, uncertainties in the timeline for Medicare coverage and the need for more commercial payer support slightly temper the outlook. Overall, the sentiment leans positive due to the potential revenue growth and strategic partnerships, but the absence of a clear timeline for Medicare approval keeps it from being strongly positive.
Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript)
Neutral9-8
LUCD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
